This bulletin covers aspects of esophageal, gastric, intestinal and colorectal cancers and should be of interest to multidisciplinary teams working in this area.
Sections can include:
· Combined Modality Therapies
· Drug and Targeted Therapies
· Pathology, Staging, Polymorphisms & Biomarkers
· Prognosis, Survival & Risk Factors
· Radiotherapy & Imaging
· Supportive Care & Symptom Management
· Surgery
Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285,
General
Berardi R, Maccaroni E, Onofri A, et al. (2014). Locally advanced rectal cancer: the importance of a multidisciplinary approach. World Journal of Gastroenterology 20,46:17279-17287.
Healthcare Improvement Scotland. Upper GI Cancer Quality Performance Indicators (Jan 2015)
Healthcare Quality Improvement Partnership. Bowel Cancer 2014 National Audit Report
Ketwaroo GA and Sawhney MS. (2015). Quality measures and quality improvements in colonoscopy. Current opinion in gastroenterology 31,1:56-61.
NICE. CG131 Colorectal cancer. (Dec 2014)
Combined Modality Therapies
Asmis T, Berry S, Cosby R, et al. (2014). Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Current Oncology 21,6:318-328.
Breugom AJ, Swets M, Bosset JF, et al. (2015). Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncology 16,2:200-207.
Dai Q, Jiang L, Lin RJ, et al. (2015). Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: A meta-analysis of randomized controlled trials. Journal of surgical oncology 111,3:277-284.
Hebbar M, Chibaudel B, Andre T, et al. (2015). FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. Annals of Oncology 26,2:340-347.
Liang JW, Zheng ZC, Yu T, et al. (2014). Is postoperative adjuvant chemoradiotherapy efficacious and safe for gastric cancer patients with D2 lymphadenectomy? A meta-analysis of the literature. European Journal of Surgical Oncology 40,12:1614-1621.
Mi K, Kalady MF, Quintini C, et al. (2015). Integrating systemic and surgical approaches to treating metastatic colorectal cancer. Surgical oncology clinics of North America 24,1:199-214
Moorcraft SY, Smyth EC and Cunningham D. (2015). Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?. Gastric Cancer 18,1:1-10.
Rombouts AJ, Koh CE, Young JM, et al. (2015). Does radiotherapy of the primary rectal cancer affect prognosis after pelvic exenteration for recurrent rectal cancer?. Diseases of the Colon & Rectum 58,1:65-73.
Wong RK, Jang R and Darling G. (2015). Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy. Journal of Gastrointestinal Oncology 6,1:89-107.
Zhou ZR, Liu SX, Zhang TS, et al. (2014). Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. Surgical oncology 23,4:211-221..
Drug & Targeted Therapies
NICE STA Guidance 326 - Imatinib for the adjuvant treatment of gastrointestinal stromal tumours. (Nov 2014)
Park HS, Jung M, Kim HS, et al. (2015). Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. Annals of Surgical Oncology 22,1:224-231.
Schmoll HJ, Twelves C, Sun W, et al. (2014). Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncology 15,13:1481-1492.
Stein A, Petersen V, Schulze M, et al. (2015). Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study. Acta Oncologica 54,2:171-178.
Uetake H, Yasuno M, Ishiguro M, et al. (2015). A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808). Annals of Surgical Oncology 22,3:908-915.
Van Cutsem E, Boni C, Tabernero J, et al. (2015). Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Annals of Oncology 26,1:149-156.
Weng W, Feng J, Qin H, et al. (2015). Molecular therapy of colorectal cancer: progress and future directions. International Journal of Cancer 136,3:493-502.
Wu AJ and Goodman KA. (2015). Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? Journal of Gastrointestinal Oncology 6,1:53-59.
Yamada Y, Higuchi K, Nishikawa K, et al. (2015). Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Annals of Oncology 26,1:141-148..
Yasui H, Muro K, Shimada Y, et al. (2015). A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. Journal of Cancer Research & Clinical Oncology 141,1:153-160.
Pathology, Staging, Polymorphisms & Biomarkers
Aoyama T, Fujikawa H, Cho H, et al. (2015). A Methylene Blue-assisted Technique for Harvesting Lymph Nodes After Radical Surgery for Gastric Cancer: A Prospective, Randomized, Controlled Study. American Journal of Surgical Pathology 39,2:266-273.
Cabalag CS, Chan ST, Kaneko Y, et al. (2015). A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology. Gastric Cancer 18,1:11-22.
Nagtegaal, I.D. (2015). Current concepts of colorectal cancer resection pathology. Histopathology 66,1:102-111.
Pullens HJ and Siersema PD. (2014). Quality indicators for colonoscopy: Current insights and caveats. World Journal of Gastrointestinal Endoscopy 6,12:571-583.
Resch A and Langner C. (2015). Risk assessment in early colorectal cancer: histological and molecular markers. Digestive Diseases 33,1:77-85.
Sawada T, Yashiro M, Sentani K, et al. (2015). New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee. Gastric Cancer 18,1:119-128.
Stintzing S, Stremitzer S, Sebio A, et al. (2015). Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. Hematology - Oncology Clinics of North America 29,1:43-60.
Sorich MJ, Wiese MD, Rowland A, et al. (2015). Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Annals of Oncology 26,1:13-21.
Sung JJ, Ng SC, Chan FK, et al. (2015). An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut 64,1:121-132.
Syngal S, Brand RE, Church JM, et al. (2015). ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. American Journal of Gastroenterology 110,2:223-262.
Prognosis, Survival & Risk Factors
Bockelman C, Engelmann BE, Kaprio T, et al. (2015). Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncologica 54,1:5-16.
Chand M, Evans J, Swift RI, et al. (2015). The Prognostic Significance of Postchemoradiotherapy High-resolution MRI and Histopathology Detected Extramural Venous Invasion in Rectal Cancer. Annals of Surgery 261,3:473-479.
Chen XZ, Wen L, Rui YY, et al. (2015). Long-term Survival Outcomes of Laparoscopic Versus Open Gastrectomy for Gastric Cancer: A Systematic Review and Meta-analysis. Medicine 94,4:e454.
Cho H, Nakamura J, Asaumi Y, et al. (2015). Long-term Survival Outcomes of Advanced Gastric Cancer Patients Who Achieved a Pathological Complete Response with Neoadjuvant Chemotherapy: A Systematic Review of the Literature. Annals of Surgical Oncology 22,3:787-792.
ESMO .Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer. (Dec 2014)
Faron M, Pignon JP, Malka D, et al. (2015). Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. European journal of cancer 51,2:166-176.
Leon O, Guren M, Hagberg O, et al. (2014). Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy & Oncology 113,3:352-358.
Mace AG, Pai RK, Stocchi L, et al. (2015). American joint committee on cancer and college of american pathologists regression grade: a new prognostic factor in rectal cancer. Diseases of the Colon & Rectum 58,1:32-44.
Moss A, Williams SJ, Hourigan LF, et al. (2015). Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR (ACE) study. Gut 64,1:57-65.
Shi Q, de Gramont A, Grothey A, et al. (2015). Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. Journal of Clinical Oncology 33,1:22-28.
Sun C, Wang Y, Yao HS, et al. (2015). Allogeneic blood transfusion and the prognosis of gastric cancer patients: Systematic review and meta-analysis. International Journal Of Surgery 13,102-110.
Zeng YJ, Zhang CD and Dai DQ. (2015). Impact of lymph node micrometastasis on gastric carcinoma prognosis: A meta-analysis. World Journal of Gastroenterology 21,5:1628-1635.
Radiotherapy & Imaging
Guren MG, Undseth C, Rekstad BL, et al. (2014). Reirradiation of locally recurrent rectal cancer: a systematic review. Radiotherapy & Oncology 113,2:151-157.
Joye I, Deroose CM, Vandecaveye V, et al. (2014). The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiotherapy & Oncology 113,2:158-165.
Lin J, Kligerman S, Goel R, et al. (2015). State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. Journal of Gastrointestinal Oncology 6,1:3-19.
Maffione AM, Lopci E, Bluemel C, et al. (2015). Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. European Journal of Nuclear Medicine & Molecular Imaging 42,1:152-163.
Nakajima I, Aoki J, Sakurai S, et al. (2015). Local massive venous invasion in colorectal cancer: CT-pathological correlation and its clinical implication. British Journal of Radiology 88,1045:20140319.
Nguyen TL, Soyer P, Fornes P, et al. (2014). Diffusion-weighted MR imaging of the rectum: clinical applications. Critical Reviews in Oncology-Hematology 92,3:279-295.
Torrance AD, Almond LM, Fry J, et al. (2015). Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer?. Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland 13,1:19-33.
Van De Voorde L, Larue RT, Pijls M, et al. (2014). A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. Radiotherapy & Oncology 113,2:166-174.
van Rossum PS, van Lier AL, Lips IM, et al. (2015). Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clinical radiology 70,1:81-95.
Yi HJ, Hong KS, Moon N, et al. (2014). Reliability of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in the nodal staging of colorectal cancer patients. Annals of Coloproctology 30,6:259-265.
Supportive Care & Symptom Management
Currie A, Askari A, Nachiappan S, et al. (2015). A systematic review of patient preference elicitation methods in the treatment of colorectal cancer. Colorectal Disease 17,1:17-25.
Grimmett C, Simon A, Lawson V, et al. (2015). Diet and physical activity intervention in colorectal cancer survivors: A feasibility study. European Journal of Oncology Nursing 19,1:1-6.
Groton M, Fisher MJ, Speroni KG, et al. (2015). A prospective, randomized, single-blind study evaluating the effectiveness, tolerability, and cost of colonoscopy bowel preparations. Gastroenterology Nursing 38,1:31-41.
Jung HW, Kim JW, Kim JY, et al. (2015). Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Supportive Care in Cancer 23,3:687-694.
Kee BK, Morris JS, Slack RS, et al. (2015). A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Supportive Care in Cancer 23,3:661-670.
Kunneman M, Marijnen CA, Rozema T, et al. (2015). Decision consultations on preoperative radiotherapy for rectal cancer: large variation in benefits and harms that are addressed. British journal of cancer 112,1:39-43.
Lee J, Jeon JY and Meyerhardt JA. (2015). Diet and lifestyle in survivors of colorectal cancer. Hematology - Oncology Clinics of North America 29,1:1-27.
Lee SY, Kang SB, Kim DW, et al. (2015). Risk factors and preventive measures for acute urinary retention after rectal cancer surgery. World journal of surgery 39,1:275-282.
Lepore SJ, Revenson TA, Roberts KJ, et al. (2015). Randomised controlled trial of expressive writing and quality of life in men and women treated for colon or rectal cancer. Psychology & Health 30,3:284-300.
North DA, Schlegel M and Martin RC 2nd. (2014). Gastroesophageal reflux disease-related symptom assessment in subjects with malignant dysphagia receiving esophageal stents. American Surgeon 80,12:1260-1265.
Park SY, Choi GS, Park JS, et al. (2015). Efficacy and safety of udenafil for the treatment of erectile dysfunction after total mesorectal excision of rectal cancer: a randomized, double-blind, placebo-controlled trial. Surgery 157,1:64-71.
Senesse P, Tadmouri A, Culine S, et al. (2015). A prospective observational study assessing home parenteral nutrition in patients with gastrointestinal cancer: benefits for quality of life. Journal of Pain & Symptom Management 49,2:183-191.e2.